DDAVP 0.3-0.4 mcg/kg IV ↑ VWF & factor VIII release. VWF binds GPIIb-IIIa receptor on platelets, causing aggregation = antiplatelet reversal.
DDAVP ↑ platelet function in patients on antiplatelet like P2Y12i (PMIDs: 18068065,1434725,8330156)
#medsky #EMsky #pharmsky #HMsky
DDAVP ↑ platelet function in patients on antiplatelet like P2Y12i (PMIDs: 18068065,1434725,8330156)
#medsky #EMsky #pharmsky #HMsky
December 5, 2024 at 2:23 AM
"Doubling up on Aspirin," he says. More likely, he is on a prescription antiplatelet or anticoagulant. But admitting to that what would mean admitting he has a serious medical issue.
January 2, 2026 at 9:15 PM
"Doubling up on Aspirin," he says. More likely, he is on a prescription antiplatelet or anticoagulant. But admitting to that what would mean admitting he has a serious medical issue.
Anticoagulation & Antiplatelet Therapy for #AFib & Stable CAD:
Meta-Analysis of RCTs
#CardioSky #Epeeps #JACC
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @bbikdeli.bsky.social @mohammadkeykhaei.bsky.social @drroxmehran.bsky.social @gbarnesmd.bsky.social @cardiacpa1.medsky.social
Meta-Analysis of RCTs
#CardioSky #Epeeps #JACC
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @bbikdeli.bsky.social @mohammadkeykhaei.bsky.social @drroxmehran.bsky.social @gbarnesmd.bsky.social @cardiacpa1.medsky.social
February 11, 2025 at 10:04 PM
Anticoagulation & Antiplatelet Therapy for #AFib & Stable CAD:
Meta-Analysis of RCTs
#CardioSky #Epeeps #JACC
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @bbikdeli.bsky.social @mohammadkeykhaei.bsky.social @drroxmehran.bsky.social @gbarnesmd.bsky.social @cardiacpa1.medsky.social
Meta-Analysis of RCTs
#CardioSky #Epeeps #JACC
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @bbikdeli.bsky.social @mohammadkeykhaei.bsky.social @drroxmehran.bsky.social @gbarnesmd.bsky.social @cardiacpa1.medsky.social
#Medsky🧪#Neurosky #publichealth
Chronic subdural hematomas (cSDH) are among the most common neurosurgical pathologies. Older adults also often have comorbidities treated with anticoagulant and antiplatelet (ACAP) medications. Managing clinicians frequently must weigh the benefits.
Chronic subdural hematomas (cSDH) are among the most common neurosurgical pathologies. Older adults also often have comorbidities treated with anticoagulant and antiplatelet (ACAP) medications. Managing clinicians frequently must weigh the benefits.
September 29, 2026 at 4:55 PM
#Medsky🧪#Neurosky #publichealth
Chronic subdural hematomas (cSDH) are among the most common neurosurgical pathologies. Older adults also often have comorbidities treated with anticoagulant and antiplatelet (ACAP) medications. Managing clinicians frequently must weigh the benefits.
Chronic subdural hematomas (cSDH) are among the most common neurosurgical pathologies. Older adults also often have comorbidities treated with anticoagulant and antiplatelet (ACAP) medications. Managing clinicians frequently must weigh the benefits.
Neither of these are doses of aspirin. Also, aspirin is an antiplatelet, not an anticoagulant (blood thinner). Also, the president is one head bonk away from a brain bleed.
Trump: "I take an aspirin a day. I don't know if it works but psychologically I need it. It thins the hell out of your blood I guess ... They want me to go down to the 80. I take the 386. I don't know what the hell it is. It's a monster. They said, 'Sir, you don't need that!'"
October 4, 2026 at 2:33 AM
Neither of these are doses of aspirin. Also, aspirin is an antiplatelet, not an anticoagulant (blood thinner). Also, the president is one head bonk away from a brain bleed.
#Medsky🧪 #oncosky #publichealth Concurrent use of antiplatelet drugs during apixaban thromboprophylaxis in cancer patients increases clinically relevant bleeding without reducing VTE.
@thjournal.bsky.social
www.sciencedirect.com/science/arti...
@thjournal.bsky.social
www.sciencedirect.com/science/arti...
Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial
Data on bleeding risk from combining prophylactic anticoagulation with drugs that have antiplatelet properties (antiplatelet agents or nonsteroidal an…
www.sciencedirect.com
April 12, 2026 at 5:47 AM
#Medsky🧪 #oncosky #publichealth Concurrent use of antiplatelet drugs during apixaban thromboprophylaxis in cancer patients increases clinically relevant bleeding without reducing VTE.
@thjournal.bsky.social
www.sciencedirect.com/science/arti...
@thjournal.bsky.social
www.sciencedirect.com/science/arti...
#hapc24 antiplatelet & anticoagulant decision tool for #palliative patients with 3 month or less prognosis
March 21, 2024 at 5:52 PM
#hapc24 antiplatelet & anticoagulant decision tool for #palliative patients with 3 month or less prognosis
#Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac Surgery
(ASSURE-DES)
Article www.jacc.org/doi/10.1016/...
Editorial www.jacc.org/doi/10.1016/...
#CardioSky #JACC #MedSky
@jaccjournals.bsky.social
(ASSURE-DES)
Article www.jacc.org/doi/10.1016/...
Editorial www.jacc.org/doi/10.1016/...
#CardioSky #JACC #MedSky
@jaccjournals.bsky.social
December 7, 2024 at 3:30 PM
#Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac Surgery
(ASSURE-DES)
Article www.jacc.org/doi/10.1016/...
Editorial www.jacc.org/doi/10.1016/...
#CardioSky #JACC #MedSky
@jaccjournals.bsky.social
(ASSURE-DES)
Article www.jacc.org/doi/10.1016/...
Editorial www.jacc.org/doi/10.1016/...
#CardioSky #JACC #MedSky
@jaccjournals.bsky.social
Risk of ICH Associated With #DOAC vs Antiplatelet Therapy
Systematic Review & Meta-Analysis
#CardioSky #MedSky #NeuroSky #Epeeps
jamanetwork.com/journals/jam...
@jama.com @ktamirisamd.bsky.social @cardiacpa1.bsky.social @vietheartpa.bsky.social @anastasiasmihaili.bsky.social @narrowqrs.bsky.social
Systematic Review & Meta-Analysis
#CardioSky #MedSky #NeuroSky #Epeeps
jamanetwork.com/journals/jam...
@jama.com @ktamirisamd.bsky.social @cardiacpa1.bsky.social @vietheartpa.bsky.social @anastasiasmihaili.bsky.social @narrowqrs.bsky.social
January 9, 2025 at 1:54 AM
Risk of ICH Associated With #DOAC vs Antiplatelet Therapy
Systematic Review & Meta-Analysis
#CardioSky #MedSky #NeuroSky #Epeeps
jamanetwork.com/journals/jam...
@jama.com @ktamirisamd.bsky.social @cardiacpa1.bsky.social @vietheartpa.bsky.social @anastasiasmihaili.bsky.social @narrowqrs.bsky.social
Systematic Review & Meta-Analysis
#CardioSky #MedSky #NeuroSky #Epeeps
jamanetwork.com/journals/jam...
@jama.com @ktamirisamd.bsky.social @cardiacpa1.bsky.social @vietheartpa.bsky.social @anastasiasmihaili.bsky.social @narrowqrs.bsky.social
A study in Nature Communications shows that comprehensive image-based profiling of circulating platelets can directly assess antiplatelet therapy efficacy and guide personalized treatment for coronary artery disease. go.nature.com/4k1St0u #medsky 🧪
May 18, 2025 at 4:12 PM
A study in Nature Communications shows that comprehensive image-based profiling of circulating platelets can directly assess antiplatelet therapy efficacy and guide personalized treatment for coronary artery disease. go.nature.com/4k1St0u #medsky 🧪
For a woman with device-detected atrial fibrillation, would you initiate anticoagulant therapy or recommend continuation of antiplatelet therapy? Read the case vignette and essays on both treatment options and cast your vote: nej.md/4lQzxTA
#MedSky #CardioSky #Afib
#MedSky #CardioSky #Afib
May 2, 2025 at 7:10 PM
For a woman with device-detected atrial fibrillation, would you initiate anticoagulant therapy or recommend continuation of antiplatelet therapy? Read the case vignette and essays on both treatment options and cast your vote: nej.md/4lQzxTA
#MedSky #CardioSky #Afib
#MedSky #CardioSky #Afib
In our recent review, we explore how demographic diversity—due to age, gender, race, ethnicity—significantly influences platelet phenotypes & responses to antiplatelet therapies.
www.cell.com/trends/pharm...
#Platelets #Age #Gender #Race #Ethnicity #Demographicdiversity #PopulationDiversity #CVD
www.cell.com/trends/pharm...
#Platelets #Age #Gender #Race #Ethnicity #Demographicdiversity #PopulationDiversity #CVD
Demographic diversity in platelet function and response to antiplatelet therapy
Recent studies have highlighted the complexity of platelet biology, revealing their diverse roles beyond hemostasis. Pathological platelet activation is now recognized as a key contributor to thrombosis and inflammation that are both central to cardiovascular disease (CVD). Emerging research emphasizes the significant impact of demographic factors – such as age, sex, race, and ethnicity – on CVD risk and responses to antiplatelet therapies. These population-based differences, shaped by genetic and non-genetic factors, highlight the need for reevaluation of antiplatelet strategies. We address current knowledge and emphasize the pressing need for further research into platelet biology and cardiovascular outcomes across diverse populations. In this review we advocate for tailored therapeutic approaches in CVD based on the recent demographic-focused findings.
www.cell.com
December 17, 2024 at 4:32 PM
In our recent review, we explore how demographic diversity—due to age, gender, race, ethnicity—significantly influences platelet phenotypes & responses to antiplatelet therapies.
www.cell.com/trends/pharm...
#Platelets #Age #Gender #Race #Ethnicity #Demographicdiversity #PopulationDiversity #CVD
www.cell.com/trends/pharm...
#Platelets #Age #Gender #Race #Ethnicity #Demographicdiversity #PopulationDiversity #CVD
Paper in this week's NEJM shows that in patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy is superior to the combination of edoxaban plus an antiplatelet drug. Major difference was in bleeding rather than reduction in ischaemic events.
December 4, 2024 at 11:25 PM
Paper in this week's NEJM shows that in patients with atrial fibrillation and stable coronary artery disease, edoxaban monotherapy is superior to the combination of edoxaban plus an antiplatelet drug. Major difference was in bleeding rather than reduction in ischaemic events.
#ESCTVOntheRoad 🚍 at #ACC25
Marco Valgimigli discusses stratified randomisation study to compare different duration of dual antiplatelet therapy after coronary stenting in either high or low bleeding risk population
Marco Valgimigli discusses stratified randomisation study to compare different duration of dual antiplatelet therapy after coronary stenting in either high or low bleeding risk population
March 29, 2025 at 6:07 PM
#ESCTVOntheRoad 🚍 at #ACC25
Marco Valgimigli discusses stratified randomisation study to compare different duration of dual antiplatelet therapy after coronary stenting in either high or low bleeding risk population
Marco Valgimigli discusses stratified randomisation study to compare different duration of dual antiplatelet therapy after coronary stenting in either high or low bleeding risk population
In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Full TARGET-FIRST trial results: nej.md/3UKJxS7
#MedSky
#MedSky
November 27, 2025 at 8:01 PM
In low-risk patients with MI and early complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy was noninferior to dual antiplatelet therapy for ischemic outcomes and led to reduced bleeding at 1 year. Full TARGET-FIRST trial results: nej.md/3UKJxS7
#MedSky
#MedSky
I actually enjoy learning the origins of nomenclature 😅
The antiplatelet names are cool
The antiplatelet names are cool
August 21, 2025 at 8:42 AM
I actually enjoy learning the origins of nomenclature 😅
The antiplatelet names are cool
The antiplatelet names are cool
I want to talk about a patient who died when I was a trainee.
He presented with an MI & was treated w/ the usual therapies along with an eptifibatide infusion (an antiplatelet gtt which was commonly used back then).
He developed agitated delirium refractory to numerous medications… #EMIMCC #1/5
He presented with an MI & was treated w/ the usual therapies along with an eptifibatide infusion (an antiplatelet gtt which was commonly used back then).
He developed agitated delirium refractory to numerous medications… #EMIMCC #1/5
a long time ago in a galaxy far far away ....
ALT: a long time ago in a galaxy far far away ....
media.tenor.com
May 10, 2025 at 9:42 PM
I want to talk about a patient who died when I was a trainee.
He presented with an MI & was treated w/ the usual therapies along with an eptifibatide infusion (an antiplatelet gtt which was commonly used back then).
He developed agitated delirium refractory to numerous medications… #EMIMCC #1/5
He presented with an MI & was treated w/ the usual therapies along with an eptifibatide infusion (an antiplatelet gtt which was commonly used back then).
He developed agitated delirium refractory to numerous medications… #EMIMCC #1/5
Anticoagulation & Antiplatelet Therapy for #AFib & Stable CAD: Meta-analysis of RCTs
Will this finally change the practice?
#CardioSky #MedSky
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @bbikdeli.bsky.social @hmkyale.bsky.social @csilvers.bsky.social @load-dependent.bsky.social
Will this finally change the practice?
#CardioSky #MedSky
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @bbikdeli.bsky.social @hmkyale.bsky.social @csilvers.bsky.social @load-dependent.bsky.social
January 21, 2025 at 9:35 PM
Anticoagulation & Antiplatelet Therapy for #AFib & Stable CAD: Meta-analysis of RCTs
Will this finally change the practice?
#CardioSky #MedSky
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @bbikdeli.bsky.social @hmkyale.bsky.social @csilvers.bsky.social @load-dependent.bsky.social
Will this finally change the practice?
#CardioSky #MedSky
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @bbikdeli.bsky.social @hmkyale.bsky.social @csilvers.bsky.social @load-dependent.bsky.social
Does DAPT need to be held prior to LP?
While it's safest to perform an LP off DAPT/antithrombotics, if an LP is pressing and it's not feasible to wait, this cohort of 100 LPs done on DAPT had a 4% rate of "bloody" taps and 0 epidural hematomas
www.mayoclinicproceedings.org/article/S002...
While it's safest to perform an LP off DAPT/antithrombotics, if an LP is pressing and it's not feasible to wait, this cohort of 100 LPs done on DAPT had a 4% rate of "bloody" taps and 0 epidural hematomas
www.mayoclinicproceedings.org/article/S002...
Safety of Lumbar Puncture Performed on Dual Antiplatelet Therapy
Practice guidelines generally recommend delaying lumbar puncture (LP) in patients
on dual antiplatelet therapy, with these recommendations often citing an increased
risk of hemorrhagic complications, ...
www.mayoclinicproceedings.org
November 11, 2024 at 6:24 PM
Does DAPT need to be held prior to LP?
While it's safest to perform an LP off DAPT/antithrombotics, if an LP is pressing and it's not feasible to wait, this cohort of 100 LPs done on DAPT had a 4% rate of "bloody" taps and 0 epidural hematomas
www.mayoclinicproceedings.org/article/S002...
While it's safest to perform an LP off DAPT/antithrombotics, if an LP is pressing and it's not feasible to wait, this cohort of 100 LPs done on DAPT had a 4% rate of "bloody" taps and 0 epidural hematomas
www.mayoclinicproceedings.org/article/S002...
From @harryspoelstra.bsky.social on Twitter:
"Important, and I'll repeat myself again based on today's science. With SarsCoV2 related endothelial inflammation, antiplatelet therapies have NO benefits! 😷..."
threadreaderapp.com/thread/18661...
"Important, and I'll repeat myself again based on today's science. With SarsCoV2 related endothelial inflammation, antiplatelet therapies have NO benefits! 😷..."
threadreaderapp.com/thread/18661...
December 9, 2024 at 9:35 PM
From @harryspoelstra.bsky.social on Twitter:
"Important, and I'll repeat myself again based on today's science. With SarsCoV2 related endothelial inflammation, antiplatelet therapies have NO benefits! 😷..."
threadreaderapp.com/thread/18661...
"Important, and I'll repeat myself again based on today's science. With SarsCoV2 related endothelial inflammation, antiplatelet therapies have NO benefits! 😷..."
threadreaderapp.com/thread/18661...
I took my last dose of Brilinta, a prescription antiplatelet medication used to lower the risk of heart attack, stroke, and cardiovascular death in patients with certain heart conditions.
I’ve been on it 2x a day since my NSTEMI on 12/23/24. My cardiologist is thrilled with my lab numbers.
I’ve been on it 2x a day since my NSTEMI on 12/23/24. My cardiologist is thrilled with my lab numbers.
December 20, 2025 at 4:50 PM
I took my last dose of Brilinta, a prescription antiplatelet medication used to lower the risk of heart attack, stroke, and cardiovascular death in patients with certain heart conditions.
I’ve been on it 2x a day since my NSTEMI on 12/23/24. My cardiologist is thrilled with my lab numbers.
I’ve been on it 2x a day since my NSTEMI on 12/23/24. My cardiologist is thrilled with my lab numbers.
Check out this paper from our group looking at antiplatelet therapy following dialysis access. Does it matter? @bosemd.com #Vascular #Dialysis
www.annalsofvascularsurgery.com/article/S089...
www.annalsofvascularsurgery.com/article/S089...
December 4, 2024 at 1:52 PM
Check out this paper from our group looking at antiplatelet therapy following dialysis access. Does it matter? @bosemd.com #Vascular #Dialysis
www.annalsofvascularsurgery.com/article/S089...
www.annalsofvascularsurgery.com/article/S089...
Antiplatelet drug ticagrelor has become firmly established for treating acute coronary syndrome, but has never quite shaken off doubts about its advantage over cheaper rivals.
With generic versions of ticagrelor about to launch, this investigation looks at the evidence www.bmj.com/content/387/...
With generic versions of ticagrelor about to launch, this investigation looks at the evidence www.bmj.com/content/387/...
December 13, 2024 at 10:03 AM
Antiplatelet drug ticagrelor has become firmly established for treating acute coronary syndrome, but has never quite shaken off doubts about its advantage over cheaper rivals.
With generic versions of ticagrelor about to launch, this investigation looks at the evidence www.bmj.com/content/387/...
With generic versions of ticagrelor about to launch, this investigation looks at the evidence www.bmj.com/content/387/...
Summary of the guideline recs for #anticoagulant & #antiplatelet therapy in ACS c/w prior recs in @americanheart.bsky.social @accintouch.bsky.social and @escardio.bsky.social guidelines. Thankful to Writing Committee & also a great team who made this summary possible:
www.jacc.org/doi/10.1016/...
www.jacc.org/doi/10.1016/...
June 4, 2025 at 12:53 AM
Summary of the guideline recs for #anticoagulant & #antiplatelet therapy in ACS c/w prior recs in @americanheart.bsky.social @accintouch.bsky.social and @escardio.bsky.social guidelines. Thankful to Writing Committee & also a great team who made this summary possible:
www.jacc.org/doi/10.1016/...
www.jacc.org/doi/10.1016/...